Evidence map›Paper›PMID 33744442›Full record

ArticleBioorganic & medicinal chemistry letters2021

Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton.

Muhamad Mustafa, Gamal El-Din A Abuo-Rahma, Amer Ali Abd El-Hafeez, Esam R Ahmed, Dalia Abdelhamid, Pradipta Ghosh, Alaa M Hayallah

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Development of FAK Inhibitors: A Five-Year Update.International journal of molecular sciences · 2022
    Review
  6. New Insights on the Nuclear Functions and Targeting of FAK in Cancer.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Muhamad MustafaPharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Gamal El-Din A Abuo-RahmaPharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Electronic address: gamal.aborahma@mu.edu.eg.
Amer Ali Abd El-HafeezPharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt; Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Esam R AhmedVACSERA, Cairo, Egypt.
Dalia AbdelhamidDepartment of Medicinal Chemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA; Department of Medicine, University of California San Diego, La Jolla, CA, USA; Rebecca and John Moore Comprehensive Cancer Center, University of California San Diego, La Jolla, CA, USA; Veterans Affairs Medical Center, La Jolla, CA, USA.
Alaa M HayallahPharmaceutical Chemistry Department, Faculty of Pharmacy, Deraya University, Minia, Egypt; Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, 71526, Egypt; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Sphinx University, New Assiut, Egypt.
Deraya UniversityCairo University · EGMinia University · EGSphinx University · EGVacsera (Egypt) · EGVeterans Health Administration · US

Funding

UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3M
Spatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4M
Integrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3M
Modulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8M
NCI NIH HHS R01 CA100768NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA238042NCI NIH HHS T32 CA121938
6 · The paper itself

Abstract

Small molecule inhibitors of the focal adhesion kinase are regarded as promising tools in our armamentarium for treating cancer. Here, we identified four 1,2,4-triazole derivatives that inhibit FAK kinase significantly and evaluated their therapeutic potential. Most tested compounds revealed potent antiproliferative activity in HepG2 and Hep3B liver cancer cells, in which 3c and 3d were the most potent (IC

Indexed as

AcetanilidesAminobenzoatesAntineoplastic AgentsApoptosisBinding SitesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorFocal Adhesion Kinase 1G1 Phase Cell Cycle CheckpointsHumansMolecular Docking SimulationPhosphorylationProtein BindingProtein Kinase InhibitorsS Phase Cell Cycle CheckpointsAcetanilidesAminobenzoatesAntineoplastic AgentsFocal Adhesion Kinase 1Protein Kinase InhibitorsPTK2 protein, humanTriazoles5-Pyridinyl-1,2,4-triazolesAnticancer activityDocking studyFAK inhibitorsSynthesis

Identifiers

PMID33744442
PMCPMC8459745
OpenAlexW3139099488

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.